What is APGE's current stock price?

APGE (Apogee Therapeutics, Inc.) is currently trading at $81.16 with a market cap of $5.02B.

What sector is Apogee Therapeutics, Inc. in?

Apogee Therapeutics, Inc. (APGE) operates in the Healthcare sector, specifically in the Biotechnology industry.

Is APGE a good stock to buy?

Analysts have a Buy consensus on APGE with a price target of $109.44. Check our detailed analysis for valuation, financials, and insider activity.

InvestLog

APGE Apogee Therapeutics, Inc.

Healthcare

$81.16-1.54%ClosedMarket Cap: $5.02B

As of 2026-05-25

Valuation

View Details

P/E (TTM)

—

PEG

—

P/B

4.50

P/S

0.00

EV/EBITDA

-15.39

DCF Value

$2.00

FCF Yield

-4.7%

Div Yield

0.0%

Margins & Returns

Gross Margin

0.0%

Operating Margin

0.0%

Net Margin

0.0%

ROE

-32.6%

ROA

-21.2%

ROIC

-24.2%

Financials

View All

Period	Revenue	Net Income	EPS
Q1 null	$0.00	$-74.1M	$—
Q4 null	$0.00	$-69.4M	$—
FY null	$0.00	$-255.8M	$—
Q3 null	$0.00	$-65.0M	$—

Analyst Ratings

View All

Consensus

Buy

Target (Consensus)

$109.44

Target (Median)

$103.00

Target Range

$83.00 - $140.00

0 Strong Buy15 Buy3 Hold0 Sell0 Strong Sell

MizuhoOutperform

2026-03-30

GuggenheimBuy

2026-03-24

Canaccord GenuityBuy

2026-03-24

CitigroupBuy

2026-03-24

BTIGBuy

2026-03-23

Trading Activity

Insider Trades

View All

HENDERSON MICHAEL THOMASdirector, officer: Chief Executive Officer

SellFri May 15

HENDERSON MICHAEL THOMASdirector, officer: Chief Executive Officer

SellFri May 15

Dambkowski Carlofficer: Chief Medical Officer

SellFri May 08

Dambkowski Carlofficer: Chief Medical Officer

SellFri May 08

Dambkowski Carlofficer: Chief Medical Officer

SellFri May 08

Related AI Research

8-K EventMay 11, 2026

APGE files 8-K — Item 2.02 Results of Operations

Apogee Therapeutics, Inc.

Company Info

Sector

Healthcare

Industry

Biotechnology

Country

Exchange

—

Beta

0.69

Apogee Therapeutics, Inc., through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD. Its earlier-stage programs include APG990, an SQ extended half-life mAb for the treatment of AD; and APG222, an extended half-life SQ antibodies for AD. The company was founded in 2022 and is based in Waltham, Massachusetts.

Peers